AR072380A1 - Composiciones farmaceuticas que comprenden derivados de aminociclohexano como el neramexano - Google Patents

Composiciones farmaceuticas que comprenden derivados de aminociclohexano como el neramexano

Info

Publication number
AR072380A1
AR072380A1 ARP090102384A ARP090102384A AR072380A1 AR 072380 A1 AR072380 A1 AR 072380A1 AR P090102384 A ARP090102384 A AR P090102384A AR P090102384 A ARP090102384 A AR P090102384A AR 072380 A1 AR072380 A1 AR 072380A1
Authority
AR
Argentina
Prior art keywords
disease
pharmaceutically acceptable
dementia
disorders
sclerosis
Prior art date
Application number
ARP090102384A
Other languages
English (en)
Inventor
Brigitte Purmann
Plitt Kirsten
Alda Szlak-Freier
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR072380A1 publication Critical patent/AR072380A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una composicion caracterizada porque comprende un compuesto seleccionado de aquellos de la formula (1) en donde R* es -(CH2)n-(CR6R7)m-NR8R9 en donde n+m = 0, 1 o 2 en donde R1 a R7 se seleccionan en forma independiente del grupo que consiste de hidrogeno y alquilo C1-6, en donde R8 y R9 se seleccionan en forma independiente del grupo que consiste de hidrogeno y alquilo C1-6 o representan en forma conjunta alquileno -(CH2)x-inferior en donde x es 2 a 5, inclusive, e isomeros opticos, enantiomeros, hidratos, solvatos, polimorfos y sus sales farmacéuticamente aceptables; y una ciclodextrina farmacéuticamente aceptable o combinacion de ciclodextrinas farmacéuticamente aceptables. Reivindicacion 7: La composicion de acuerdo con cualquier reivindicacion precedente, caracterizada porque el compuesto de la formula (1) es neramexano o una sal farmacéuticamente aceptable del mismo. Reivindicacion 13: Uso de una composicion de acuerdo con cualquiera de las reivindicaciones 1 a 11 caracterizado porque es para la fabricacion de un medicamento para tratar un trastorno del SNC o una condicion seleccionada de hipoxia, hipoglucemia, encefalopatía hepática, enfermedades neurodegenerativas cronicas, demencia, enfermedad de Alzheimer, demencia vascular, enfermedad de Parkinson, enfermedad de Huntington, esclerosis multiple, esclerosis lateral amiotrofica, neurodegeneracion por SIDA, demencia relacionada con SIDA, atrofia olivopontocerebelar, síndrome de Tourette, enfermedad de la neurona motora, disfuncion mitocondrial, síndrome de Korsakoff, enfermedad de Creutzfeldt-Jakob, dolor cronico, dolor agudo, tolerancia a la droga, dependencia y adiccion (por ej., opioides, cocaína, benzodiazepinas, y alcohol), dolor neuropático, epilepsia, depresion, ansiedad, esquizofrenia, espasticidad, nistagmo, enfermedades oculares, acufenos, encefalopatía hepática, esclerosis multiple, accidente cerebrovascular, disquinesia, malaria, e infecciones virales tales como hepatitis C y virus de la enfermedad de Borna, condiciones que requieren un inmunomodulador, emesis, trastornos por abuso de drogas y alcohol, trastornos cognitivos, temblor cerebeloso, y trastornos del apetito.
ARP090102384A 2008-06-26 2009-06-26 Composiciones farmaceuticas que comprenden derivados de aminociclohexano como el neramexano AR072380A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13316208P 2008-06-26 2008-06-26
EP08011633 2008-06-26

Publications (1)

Publication Number Publication Date
AR072380A1 true AR072380A1 (es) 2010-08-25

Family

ID=40042958

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102384A AR072380A1 (es) 2008-06-26 2009-06-26 Composiciones farmaceuticas que comprenden derivados de aminociclohexano como el neramexano

Country Status (15)

Country Link
US (1) US20110092600A1 (es)
EP (1) EP2310053A1 (es)
JP (1) JP2011525513A (es)
KR (1) KR20110015445A (es)
CN (1) CN102046204A (es)
AR (1) AR072380A1 (es)
AU (1) AU2009262490A1 (es)
BR (1) BRPI0914768A2 (es)
CA (1) CA2722147A1 (es)
IL (1) IL210163A0 (es)
MX (1) MX2010013451A (es)
RU (1) RU2011102784A (es)
TW (1) TW201006463A (es)
WO (1) WO2009156160A1 (es)
ZA (1) ZA201008242B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033651A1 (en) * 2007-09-12 2009-03-19 Merz Pharma Gmbh & Co. Kgaa Titration package for neramexane and its use in the treatment of an inner ear disorder
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
KR20130087379A (ko) * 2010-06-18 2013-08-06 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노-알킬시클로헥산 유도체의 국소 사용을 위한 겔 제형
WO2012010415A1 (en) 2010-07-22 2012-01-26 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition containing a tryptophan derivative
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
DE102017004149A1 (de) 2017-05-02 2018-11-08 Azur Space Solar Power Gmbh Lichtempfangseinheit
WO2021222888A1 (en) * 2020-05-01 2021-11-04 University Of Southern California Cyclodextrin based anti-microbial therapy
CN114886945B (zh) * 2022-05-10 2023-07-07 西安外事学院 一种调节嘌呤代谢的超分子药物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237128B (it) * 1989-11-10 1993-05-18 Magis Farmaceutici Composti ad attivita' espettorante ottenuti per complessazione del trans-4-(2-ammino-3,5-dibromo-benzilammino)cicloesanolo con una ciclodestrina, loro preparazione e loro utilizzazione
PT1009732E (pt) * 1997-06-30 2003-10-31 Merz & Co Gmbh & Co 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2006108055A1 (en) * 2005-04-05 2006-10-12 Yale University Glutamate modulating agents in the treatment of mental disorders
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine

Also Published As

Publication number Publication date
IL210163A0 (en) 2011-03-31
CA2722147A1 (en) 2009-12-30
JP2011525513A (ja) 2011-09-22
AU2009262490A1 (en) 2009-12-30
WO2009156160A1 (en) 2009-12-30
ZA201008242B (en) 2011-07-27
US20110092600A1 (en) 2011-04-21
RU2011102784A (ru) 2012-08-10
MX2010013451A (es) 2011-03-21
BRPI0914768A2 (pt) 2015-10-20
EP2310053A1 (en) 2011-04-20
KR20110015445A (ko) 2011-02-15
CN102046204A (zh) 2011-05-04
TW201006463A (en) 2010-02-16

Similar Documents

Publication Publication Date Title
AR072380A1 (es) Composiciones farmaceuticas que comprenden derivados de aminociclohexano como el neramexano
MX2017011951A (es) Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
PE20191406A1 (es) N-[4-fluoro-5-[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
EA201692052A1 (ru) Циклопропанаминовое соединение и его применение
WO2018015573A3 (en) Trem2 cleavage modulators and uses thereof
MA35739B1 (fr) Dérivés de sulfure de trifluoréthyle n-substitudé d'arylamidine en tant qu'acaricide et insecticide
CO2019006785A2 (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
AR107928A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
CL2011003205A1 (es) Compuesto 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina; composicion farmaceutica; y su uso para el tratamiento de un trastorno neurodegenerativo, tales como alzheimer y demencias.
JP2018523665A5 (es)
EA201692558A1 (ru) Производные индолин-2-она или пирролопиридин-2-она
JP2011530521A5 (es)
AR065815A1 (es) Compuestos de dihidroindazol en el tratamiento de trastornos del hierro
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
NZ601967A (en) Pde10 inhibitors and related compositions and methods
AR097088A1 (es) Derivados de 1,7-naftiridina
BR112019004243A2 (pt) composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente
JP2010520884A5 (es)
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
JP2017519798A5 (es)
CY1120148T1 (el) Ενωσεις ουριας και η χρηση τους ως ενζυμικοι αναστολεις
ECSP088477A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
UY38027A (es) Moduladores de molécula pequeña del dominio btb de keap1
BR112017025135A2 (pt) processos para isolar um composto e para preparar um composto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal